The Innovative Target Exploration Network (ITEN) is the new, early-stage partnering model established by Pfizer in order to run collaborative relationships with select academic institutions and principal investigators around the world. The first three academic institutions to adhere to the ITEN model are UK’s University of Cambridge and University of Oxford and US’s University of Texas Southwestern. The Cambridge and Oxford University research projects each will focus on deubiquitinylation enzymes (DUBs), while the UTSW research project aims to elucidating new genetic targets, particularly in oncology and metabolic disease.

LEAVE A REPLY

Please enter your comment!
Please enter your name here